Proposed Supportive Pulmonary Surfactant for the Treatment of COVID-19 Infection

The spread of SARS-cov-2, has been in continuous progression for over two years, and despite the many treatments proposed and vaccinations none of these has been able to eliminate the pathology.

In this work, we suggest for the first time the use of Pulmonary Surfactant (PS) replacement treatment in patients admitted to intensive care. Pulmonary Surfactant is commonly used to treat Acute Respiratory Distress Syndrome (ARDS) in premature babies, and it has demonstrated to be quite effective. Because ARDS, also known as hyaline membrane illness, shares many pathogenetic and symptomatological features with SARS-CoV-2 infection, it may be beneficial to utilize Pulmonary Surfactant as an adjunct to current therapies. Even medications with low absorption and bioavailability can be delivered straight into the most hidden alveolar locations using the surfactant we propose in our investigation.